Urothelial tumors develop along two distinctive phenotypic pathways (super®cial papillary non-invasive tumors versus¯at carcinoma in situ lesions), with markedly dierent biological behavior and prognosis. Although multiple genetic alterations have been identi®ed in human bladder cancer, their cause ± eect relationship with the two pathways has not been ®rmly established. Using a urothelium-speci®c promoter of the uroplakin II gene, we showed earlier in transgenic mice that the urothelial expression of SV40T antigen, which inactivates p53 and pRb, induced carcinoma in situ and invasive and metastatic bladder cancer. In striking contrast, we demonstrate here that the urothelial expression of an activated Ha-ras in transgenic mice caused urothelial hyperplasia and super®cial papillary non-invasive bladder tumors. These results provide strong, direct experimental evidence that the two phenotypical pathways of bladder tumorigenesis are caused by distinctive genetic defects. Our results indicate that Ha-ras activation can induce urothelial proliferation in vivo; and that urothelial hyperplasia is a precursor of low-grade, super®cial papillary bladder tumors. Our transgenic models provide unique opportunities to study the detailed molecular events underlying dierent types of bladder neoplasms, and can serve as useful preclinical models for evaluating the in vivo ecacy of preventive and therapeutic agents that act on various signaling pathways in bladder cancer.
Introduction
A cornerstone in the investigation of the urothelial carcinoma is the recognition of the two major phenotypic tumor variants (Koss, 1992) . The ®rst variant, which accounts for 70 ± 80% of the urothelial carcinomas, presents as super®cial, papillary lesions that are often multifocal, recurrent, but only infrequently progress to muscle-invasive stage (Grossman, 1996) . If treated promptly, the 5-year survival rate of this variant can approach 90%. The second variant (accounting for 20 ± 30%) presents as an invasive tumor at diagnosis, and has a very high risk of progressing to incurable distant metastases (Steinberg et al., 1992) . Clinical and histopathological data strongly suggest that the majority of the invasive urothelial carcinomas are not derived from the super®cial papillary tumors, but from a unique precursor lesion, i.e.,¯at carcinoma in situ (CIS), or can arise de novo (Schalken et al., 1992; Steinberg et al., 1992) . Thus, urothelial carcinomas appear to develop and progress via two distinctive phenotypic pathways with drastically dierent biological behavior and clinical outcome.
Recent genetic analyses suggest that the dierent genetic defects may underlie the two bladder tumorigenesis pathways. Notably, deletions involving chromosomes 9p and 9q are frequently found in super®cial papillary tumors, whereas dysfunction of p53 and pRb is primarily associated with CIS and invasive tumors (Dalbagni et al., 1993; Spruck et al., 1994; Rosin et al., 1995; Wagner et al., 1995) . However, with the exception of several chemical carcinogenesis models (Oyasu, 1995; Ogawa et al., 1998) , most of the clinical data are correlative in nature. Moreover, since multiple genetic alterations are simultaneously present in human bladder cancer, the role of a single genetic defect in inducing urothelial tumorigenesis has been dicult to ascertain. Even less is known about the role of other genetic abnormalities that are also prevalent in human bladder cancer, such as the activation of ras, and the overexpression of genes encoding erbB-2, c-myc, and epidermal growth factor receptor (Czerniak et al., 1992; Messing, 1992; Cordon-Cardo et al., 1994; Rezniko et al., 1996) .
The identi®cation of uroplakins as the ®rst urothelium-speci®c genes has made it possible to study the roles of oncogenic events in urothelial tumorigenesis using the transgenic approach. Using a 3.6 kb mouse uroplakin II promoter, we previously targeted an SV40 large T oncogene to the urothelium and showed that this oncogene induced bladder carcinoma in situ which then advanced to become invasive and metastatic bladder cancer (Zhang et al., 1999) . Since SV40 large T antigen can inactivate p53 and pRb, two genetic defects prevalent in human invasive bladder cancers, this ®nding strongly suggests that the dysfunction of these two tumor suppressor proteins can induce the formation of the aggressive form of the urothelial carcinoma (Zhang et al., 1999) .
In this study, we examined the role of Ha-ras activation in the two pathways of bladder tumorigenesis by expressing an activated Ha-ras in the urothelium of transgenic mice. The members of the ras gene family play a central role in transducing mitogenic signals from the cell surface receptors to the nucleus (Cahill et al., 1996) . Mutations of ras, occurring predominantly at hotspots in codons 12, 13 and 61, are detected in about 30% of all human tumors, making ras the most frequently mutated oncogene (Bos, 1989) . A common consequence of each of these mutations is the constitutive activation of downstream kinase cascades and transformation of immortalized cells in vitro. Ras activation is thus important in not only the genesis but also the maintenance of the solid tumors (Amundadottir and Leder, 1998; Chin et al., 1999) .
Although ras activation was ®rst identi®ed in bladder cancer (Capon et al., 1983) , controversies existed regarding its precise role in urothelial tumorigenesis. First, the frequency of Ha-ras mutations in bladder cancer ranged anywhere from 6 to 70% in dierent reports (Visvanathan et al., 1988; Burchill et al., 1991 Burchill et al., , 1994 Czerniak et al., 1992; Saito, 1992; Knowles and Williamson, 1993; Levesque et al., 1993; Fitzgerald et al., 1995) . Second, the stage in which ras mutation occurs varies from early to late or to no stage-correlation (Theodorescu et al., 1990; Czerniak et al., 1992; Knowles and Williamson, 1993; Burchill et al., 1994; Fitzgerald et al., 1995) . Third, transfection of an activated ras into primary cultured ®broblasts provoked premature senescence which could be overcome by the inactivation of tumor suppressor genes p53 and p16; this suggests that the activated ras requires the cooperative activity of another oncogenic event to fully transform primary cultured ®broblasts (Serrano et al., 1997) . Therefore, many questions regarding the biological roles of Ras activation in bladder tumorigenesis remained unanswered. By expressing an activated Ha-ras in mouse urothelium, we sought to determine whether Ha-ras alone would be sucient to elicit urothelial tumor formation; and if so, whether ras-induced tumors would mirror one of the two pathways of bladder formation and progression. Our results demonstrate that Ha-ras activation is a potent growth signal for urothelium, and that it induces exclusively the super®cial papillary tumors of the bladder. These results, combined with our earlier data that SV40 T antigen, which inactivates p53 and pRb, induced CIS and invasive bladder carcinomas, provide strong experimental evidence that dierent genetic defects are responsible for the two distinctive pathways of bladder tumor formation.
Results

Generation of transgenic mice expressing an activated Ha-ras in the bladder
To study the role of Ha-ras activation in bladder tumorigenesis, we generated transgenic mice expressing this gene speci®cally in the urothelium. We constructed a fusion gene composed of the murine UPII gene promoter and a 3.0 kb activated c-Ha-ras harboring a point mutation at codon 61 of the second exon converting CAG (encoding glutamine) to CTG (leucine) (Corominas et al., 1991;  Figure 1 ). This ras mutant, like those involving codons 12 and 13, has been shown to activate the kinase signaling pathway and transform immortalized cells in vitro (Corominas et al., 1991) . The mUPII/Ha-ras-M fusion gene was injected into the fertilized eggs of strain FBV/N inbred mice. Of the 20 live-born animals, three integrated the gene in the genome. Southern blotting using a UPII probe detected, in addition to a 4.0 kb endogenous UPII fragment, two transgene fragments (4.9 and 8.2 kb) in founders 2 (48 copies) and 12 (30 copies), and one fragment (8.2 kb) in founder 5 (two copies) ( Figure 1b and Table 1 ). A Ha-ras probe con®rmed the same transgene patterns and a 0.8 kb endogenous Haras gene fragment (Figure 1b) . Restriction mapping showed that the 4.8 and 8.2 kb mUPII/Ha-ras fragments correspond to the`head-to-tail' and`tailto-tail' transgene con®guration, respectively. The expression of rabbit Ha-ras in mouse bladders was con®rmed by RT ± PCR using progenies of founder 5 (Figure 1d ). Western blotting using a pan-ras antibody revealed, in addition to the endogenous mouse Ha-ras, a fast-migrating mutant Ha-ras exclusively in transgenic mice (Figure 1e ; Fasano et al., 1984) . These results established the speci®c expression of the activated Ha-ras in the urothelial cells of the transgenic mice.
Mice harboring low copy of mUPII/Ha-ras-M developed urothelial hyperplasia followed by superficial papillary tumors Although transgenic line 5 (two copies of the transgene) appeared outwardly healthy, histological examination of the urinary bladders revealed a range of age-dependent morphological alterations. The urothelium of the newborns appeared normal with three layers ( Figure 2a) ; however, at 3 ± 5 months it became thickened to 6 ± 7 cell layers with strong PCNA nuclear staining (Figure 2b ,e) and weak ras staining (Figure 2g ) of all cell layers. Nevertheless, the epithelium retained its overall organization and polarity, thus representing simple hyperplasia (Figure 2b ). At about 8 months, the urothelium became more hyperplastic, forming localized epithelial nodules (nodular hyperplasia) ( Figure  2c ). None of the 24 mice analysed between 3 and 8 months of age formed bladder tumors. However, from 10 to 26 months of age, 10 of 16 (63%) mice developed super®cial papillary bladder tumors which were highly dierentiated with abundant cytoplasm and little nuclear pleomorphism or atypia, and which remained non-invasive during the 26-month observation period (Figure 2h ,i). In those mice that developed bladder papillary tumors, intervening urothelium exhibited simple or nodular hyperplasia (data not shown). Mice (6/16) that did not develop super®cial papillary tumors invariably exhibited simple and nodular urothelial hyperplasia. None of the 51 negative control mice exhibited any urothelial abnormalities throughout the 28 month observation period (Table 1) .
Mice harboring high copy of mUPII/Ha-ras-M developed early-onset superficial papillary tumors Founder mice F0.2 (48 copies of the transgene) and F0.12 (30 copies) succumbed to death at 4 and 5 months, respectively; and their bladders, ureters and kidneys were signi®cantly enlarged ( Figure 3a) . The bladders had developed tumors which appeared as pedunculated, narrow-based polyps protruding into the bladder lumen. Histologically, the urothelium was markedly thickened to 20 ± 30 cell layers ( Figure  3b ,c,e) with a high level expression of PCNA ( Figure  3f ) and ras ( Figure 3e ; versus low expression in normal urothelium, Figure 3d ). Intraepithelial neovascularization and pseudoglandular structure, both of which are frequently encountered in human bladder papillary tumors, were prevalent in these mouse bladder tumors ( Figure 3c ). Like the low-copied mice, the proliferating epithelial cells in these high-copied mice were highly dierentiated, had little nuclear atypia and were noninvasive. Analysis of the kidneys revealed highly dilated renal pelvis and atrophic renal papilla (data not shown). This may be because of the obstruction of urine¯ow due to large bladder tumors resulted in hydronephrosis, which led to renal dysfunction and failure, thus explaining the early death of these mice. One of the founder mice (F0.12) also developed a papillary tumor in the renal pelvis (Figure 3h ), which is lined with urothelium, synthesizes the uroplakins, thus also expressing the activated Ha-ras.
To determine whether urothelial hyperplasia preceded the super®cial papillary tumors, we sacri®ced high-copy-numbered mUPII/Ha-ras F1 mice at 1 month of age (Table 1) . Bladders of all mice examined exhibited urothelial hyperplasia (data not shown). The fact that hyperplasia preceded the papillary tumors in high-copied transgenic mice, that mice with urothelial Mouse tail DNAs were digested with SacI, electrophoresed, transferred to nylon membrane and hybridized with either a mouse UPII probe (P1 in a) or a ras probe (P2). Note the detection of a 4.9 kb and an 8.2 kb transgenic fragments in founders 2 and 12, but only an 8.2 kb transgene fragment in founder 5. These two dierent-sized transgene fragments represent the`head-to-tail' and`tail-to-tail' transgene orientation. The 4.0 kb band corresponds to an endogenous UPII fragment. The 0.8 kb band detected by the ras probe is an endogenous mouse ras fragment. Transgene-negative mice (lanes marked with ± ) were used as controls. (c) Con®rmation of transgene in F1 mice of the F0.5 line by a dierent (NcoI) restriction digestion and UPII probe hybridization. The 1.7 kb fragment was detected only in the transgenic litters (lanes 2 ± 6), whereas the 1.4 kb band was detected in all mice including the negative control (lane 1). (d) Urothelial expression of the activated Ha-ras transgene in line No. 5. RT ± PCR of urothelial total RNA using primers speci®c for the activated rabbit Ha-ras (top panel), endogenous mouse ras (middle panel) and for G3PDH as a PCR control (lower panel). Note the expression of the activated Ha-ras in transgenic mice (lanes 3 ± 5), but not in normal control mouse (lane 2). Lane 1 is a PCR reaction using as a template a plasmid containing the activated Ha-ras transgene. (e) Upper panel: immunoblotting of total urothelial proteins after they were transferred onto nitrocellulose using a pan-ras antibody, showing the overexpression of a fast-migrating mutant Ha-ras species in transgenic mice of line No. 5 (lane 2), and an endogenous ras in normal mice (lane 1). H chain shows endogenous antibody contamination in total protein extracts. Lower panel: duplicate lanes were blotted with an anti-uroplakin II (UPII) to serve as a loading control hyperplasia at young age eventually developed papillary tumors in low copied mice, and that these two changes coexisted in the same bladder, strongly indicates that urothelial hyperplasia is a precursor of super®cial papillary tumor.
Discussion
Activating mutation of Ha-ras exerts a potent tumorigenic effect on urothelium
We provide evidence here that urothelium-speci®c expression of an activated Ha-ras causes urothelial hyperplasia and super®cial papillary bladder tumors, indicating that ras activation exerts a potent, proliferative eect on urothelial cells. The fact that the transgenic mice harboring high transgene copies developed at birth generalized urothelial hyperplasia which evolved into bladder tumors at early ages, strongly suggests that activating mutation of Ha-ras, concurrent with overexpression, represents a nonclonal event which is sucient to elicit bladder tumors. Our ®ndings therefore establish that ras activation can be an early event in bladder tumor formation.
Overexpression of the ras oncogene as achieved in our transgenic model is relevant in bladder tumorigenesis in two respects. First, overexpression of ras protooncogene occurs frequently in human bladder tumors. Vageli et al. (1996) quanti®ed the ras transcripts in paired tumor and adjacent normal tissue and found ras overexpression in about 40% of tumor specimens. Others found ras overexpression at the protein level in more than 50% of the bladder tumors (Dunn et al., 1988; Ye et al., 1993) . Second, a range of extracellular growth signals function through the ras signaling pathway (Olson and Marais, 2000) . For example, epidermal growth factor receptor (EGFr), a tyrosine kinase receptor, functions by activating the ras/raf/MAP kinase pathway. Interestingly, it has been suggested that EGFr is frequently activated in bladder cancer because the receptor is overexpressed in about 50 ± 60% of human bladder cancers, and because mammalian urine naturally contains abundant EGF (Messing, 1992) . Therefore, ras activation can have three dierent forms: activating mutation, overexpression and functional activation of the signaling pathway; all three forms may contribute to the genesis of bladder tumors. The ability of an activated Ha-ras to readily induce urothelial tumors may also be related to the apparent high susceptibility of the urothelium to this particular oncogene. Data generated from other transgenic systems reveal that Ha-ras exhibits a spectrum of oncogenic capabilities depending on the tissues under study (Rassoulzadegan and Cuzin, 1987; Schneider and Bowden, 1992) . For instance, activated Ha-ras speci®-cally expressed in the epidermis induced papillomas, but only upon wounding or phorbol ester treatment (Leder et al., 1990) . The same oncogene expressed in pancreas and liver eciently induced hyperplasias very early with subsequent tumor development (Brinster and Palmiter, 1986; Quaife et al., 1987; Sandgren et al., 1989) . In contrast, activated Ha-ras driven by the metallothionein promoter failed to induce any tumors in mice (Brinster and Palmiter, 1986) . These studies support the notion that oncogenic susceptibility is tissue-speci®c (Rassoulzadegan and Cuzin, 1987) . Unlike epidermal and intestinal epithelia which rapidly proliferate, urothelium has an extremely low proliferative rate with a labeling index of only 0.02 ± 0.05% (Walker, 1960) . The overexpression of activated Haras, a potent growth signal, in urothelium can suciently counter terminal dierentiation and dramatically increase cell proliferation, leading to tumorigenesis (Figures 2 and 3 ; Table 1 ).
The fact that bladder tumors in low-copied mice developed localized, super®cial papillary tumors with a much longer latency suggests that, in the absence of overexpression, Ha-ras activation requires a secondary event, either genetic or epigenetic, to fully induce bladder tumors. This event could be the activation and/or overexpression of another oncogene, the overexpression of a growth factor receptor, the dysfunction of tumor suppressor genes, or increased synthesis of vascular growth factors (Campbell et al., 1998 ; Orntoft and Wolf, 1998). Our transgenic model should be useful for identifying synergistic events and the mechanisms by which they contribute to bladder tumor progression.
Different genetic defects underlie two phenotypic variants of bladder tumors
Our transgenic model expressing the activated Ha-ras developed exclusively urothelial hyperplasia and lowgrade, super®cial, papillary tumors. Remarkably, none of these tumors were invasive during the 26 month observation period (Figures 3 and 4) . This is in sharp contrast to our previously established, four independent lines of transgenic mice overexpressing the SV40T oncogene, which developed high-grade carcinoma in situ. These lesions readily progressed to muscle-invasive and metastatic bladder cancer (Zhang et al., 1999) . The phenotypes and progression modes of tumors in these two models strongly resemble the two phneotypic variants of bladder cancer in humans (Koss, 1992) . Recent data on the genetic alterations in human bladder cancer have led to the proposal that dierent genetic defects are responsible for the two dierent bladder cancer variants. Since the dysfunction of p53 and pRb, two major tumor suppressor genes, is primarily detected in CIS and invasive bladder cancer, it has been suggested that defects in these two genes can result in the aggressive variant of bladder cancer (Spruck et al., 1994; Rosin et al., 1995; Rezniko et al., 1996) . Our previous transgenic model expressing the SV40T, which can inactivate p53 and pRb (Bryan and Reddel, 1994) , indeed developed exclusively CIS and invasive bladder tumors, thus providing experimental evidence supporting the existence of this pathway (Zhang et al., 1999) . Our current study provides direct evidence linking ras activation to some of the super®cial papillary bladder tumors ( Figure  4 ). Since not all super®cial papillary tumors in humans harbor Ha-ras mutations, our study can not exclude the possibility that other genetic defects can also cause the super®cial, papillary variant of bladder tumors. For instance, the defect of p16, a cyclin-kinase inhibitor and tumor suppressor, has recently been shown to be associated with human super®cial papillary tumors (Orlow et al., 1995; Balazs et al., 1997; Benedict et al., 1999) . Studies are underway to determine the potential involvement of p16 defect in the activated ras-induced transgenic bladder tumors. Since human super®cial papillary tumors are frequently associated with 9p and 9q deletions (Dalbagni et al., 1993; Spruck et al., 1994) , it will also be important to identify and correlate any potential cytogenetic abnormalities in these transgenic mice.
Tumor phenotypes vary in rodent bladder carcinogenesis models
An interesting phenomenon in chemical carcinogenesis models of bladder cancer is that the same carcinogens appear to cause dierent bladder tumors in rats than in mice (Oyasu, 1995; Ogawa et al., 1998) . In rats, bladder tumors are frequently of the papillary type, irrespective of the carcinogens used, and they are rarely invasive unless large doses of carcinogens was used for a prolonged period (Kunze and Chowaniec, 1990) . In mice, however, the same carcinogens can cause primarily urothelial dysplasia and CIS, the latter of which readily becomes invasive (Ohtani et al., 1986; Ogawa et al., 1998) . The reason for this species variability is not entirely clear, but existing data suggest that it is the speci®c genetic defects, rather than the genetic background per se, that determine the dierent phenotypes. In carcinogen-induced rat bladder tumors, there is a high frequency of Ha-ras mutation and low frequency of p53 mutation (Enomoto et al., 1990; Masui et al., 1993) . In contrast, the same carcinogen-induced mouse bladder tumors contain a high frequency of p53 mutations and a low frequency of Ha-ras mutations (Yamamoto et al., 1995; Ogawa et ., 1998) . Therefore, the dierent genetic background in rats and mice may contribute indirectly to the varying types of genetic defects that will occur in response to the same carcinogen treatment, i.e., either Ha-ras activation, which produces super®cial papillary tumors, or p53 mutation, which produces CIS/invasive tumors. This is in fact the case because the activated Ha-ras is indeed capable of inducing the papillary tumors in our transgenic mice.
Potential applications of the UPII/Ha-ras-M transgenic model
Our transgenic model opens a door to many interesting experiments. Thus, these animals can be used to study synergistic interaction of Ha-ras oncogene with other oncogenes, including erb-B2, c-myc and growth factors such as epidermal growth factor receptor, which is frequently overexpressed in bladder cancer (Rezniko et al., 1996; Orntoft and Wolf, 1998) . It can also be used to study the cooperation between the Ha-ras oncogene and tumor suppressor genes, p53, pRb and p16, all of which have been proposed to play critical roles in bladder tumor formation and progression. In both cases, bi-transgenic mice could be developed harboring two well-de®ned genetic alterations and tumor progression can be followed sequentially. Finally, because farnesyl transferase plays a critical role in the membrane targeting of Ha-ras, hence its signaling, inhibitors of the enzyme have been proposed to have signi®cant value in treating various human cancers (Gibbs et al., 1994 ). This transgenic model should serve as an excellent pre-clinical model for evaluating the ecacy of various farnesyl transferase inhibitors for treating bladder cancer.
Materials and methods
Construction of transgene and generation of transgenic mice
A 3.0 kb EspI rabbit Ha-ras genomic fragment harboring a A : T to T : A transversion mutation at codon 61 (Corominas et al., 1991) , which converts its encoded valine to leucine, was blunt-ended using Klenow DNA polymerase large fragment and cloned onto the SmaI site of the pBluescript SK+. The Ha-ras mutant (Ha-ras-M) fragment was retrieved by digestion with BamHI and HindIII, and sub-cloned downstream of the 3.6 kb murine UPII promoter that was previously inserted into pUC18 vector (Lin et al., 1995) . Correct orientation of the fusion gene was established by polymerase chain reaction (PCR) using a sense primer within the UPII promoter and an antisense primer within the Haras-M as well as by sequencing the junction region. The UPII/Ha-ras-M fusion gene was excised en bloc by KpnI and HindIII, gel-puri®ed and injected into the pronuclei of one cell FVB/N mouse embryos according to established protocols (Brinster et al., 1981) .
Southern blot analysis
Southern blotting was used to identify transgenic mice and to quantify transgene copy number. Mouse tail DNA was extracted using proteinase K digestion and salt precipitation. The DNA was digested with SacI and probed independently with the 32 -P-labeled UPII probe and the rabbit Ha-ras probe. After autoradiography, the X-ray ®lm was scanned by a densitometer and the copy number of the transgene was determined by comparing the relative density of the transgene with that of the endogenous UPII gene. The tail DNA of some F1 mice was also digested with NcoI to better resolve the transgene and the endogenous UPII gene.
RNA extraction and RT ± PCR
Transgene expression in mouse urothelium was determined by reverse-transcription/polymerase chain reaction (RT ± PCR). Brie¯y, total RNA was extracted from urothelial cells scraped o from inside-out mouse bladders using a total RNA extraction kit (Promega, Madison, WI, USA). One microgram of the total RNA was reverse-transcribed and subjected to PCR using primers designed in regions that were divergent between the transgene (rabbit) and the endogenous (mouse) Ha-ras. This would distinguish the expression of the transgene from that of the endogenous Ha-ras gene. The sense and anti-sense primers for rabbit Ha-ras were: CATGTCTACTGGACTACTTA and TCTTGGCTGATG-TTTCAATG, and for mouse Ha-ras were: CGGCGG-TGTAGGCAAGAGCGCC and TCTTGGCCGAGGTCTC-GATA. PCR was performed at the following conditions: 948C for 5', 558C for 30', 728C for 1' for 35 cycles and 948C for 5', 558C for 30', 728C for 8' for the last cycle. Primers speci®c for the mouse glyceraldehyde phosphate dehydrogenase gene were included in PCR reactions as a normalization control.
Immunoblot analysis
Transgene expression was also assessed at the protein level using immunoblotting. Total urothelial proteins were dissolved in 1% SDS, separated on a 12.5% SDS ± PAGE, electrotransferred onto a nitrocellulose membrane and blotted with a monoclonal pan Ha-ras antibody (Quality Biotech, Camden, NJ, USA) (Fasano et al., 1984) . After incubation with a secondary goat-anti-moue antibody conjugated with horseradish peroxidase, the membrane was developed in a solution containing diamine benzidine and H 2 O 2 . A rabbit UPII antibody was used as a normalization control. Parallel experiments were performed using urothelial proteins from the transgene-negative mouse bladders.
Histopathology and immunohistochemistry
Dissected mouse tissues were ®xed in 10% buered formalin, dehydrated, embedded in paran and sectioned at 5 mm. For histopathological survey, sections were deparanized and stained with hematoxylin and eosin. For assessing the Ha-ras expression, deparanized sections were microwaved in citrate buer (pH 6.0) for 20 min and stained with a monoclonal pan-ras antibody. For assessing the proliferative status of urothelium, a peroxidase-conjugated rat antibody against proliferative cell nuclear antigen (DAKO, Carpinteria, CA, USA) was used directly to stain deparanized sections.
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